{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:52:37Z","timestamp":1788051157475,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"am","delay-in-days":259,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cyto.2019.154859","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T23:05:31Z","timestamp":1571267131000},"page":"154859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits"],"prefix":"10.1016","volume":"126","author":[{"given":"Daniel","family":"Bertin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Serrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Charles","family":"Grimaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadne","family":"Desjeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Desplat-J\u00e9go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2019.154859_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s Disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.cyto.2019.154859_b0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","article-title":"Review article: causative factors and the clinical management of patients with Crohn\u2019s disease who lose response to anti-TNF-\u03b1 therapy","volume":"34","author":"Danese","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2019.154859_b0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0025","first-page":"444","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.cyto.2019.154859_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MIB.0000436951.80898.6d","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"O\u2019Meara","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.cyto.2019.154859_b0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","article-title":"Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease","volume":"34","author":"Steenholdt","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2019.154859_b0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/art.39841","article-title":"Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis","volume":"69","author":"Bejan-Angoulvant","year":"2017","journal-title":"Arthrit. Rheumatol. Hoboken NJ."},{"key":"10.1016\/j.cyto.2019.154859_b0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/MCG.0000000000000441","article-title":"Are anti-tumor necrosis factor trough levels predictive of mucosal healing in patients with inflammatory bowel disease?: a systematic review and meta-analysis","volume":"50","author":"Barnes","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0050","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0055","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/flgastro-2012-100241","article-title":"Value of drug level testing and antibody assays in optimising biological therapy","volume":"4","author":"Vermeire","year":"2013","journal-title":"Frontline. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0065","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cyto.2019.154859_b0070","first-page":"654","article-title":"A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn\u2019s disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.cyto.2019.154859_b0075","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cyto.2019.154859_b0080","article-title":"Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn\u2019s disease patients who lose response to infliximab","volume":"3","author":"Roblin","year":"2015","journal-title":"J. Mark Access Health Policy."},{"key":"10.1016\/j.cyto.2019.154859_b0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","article-title":"Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review","volume":"52","author":"Martelli","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00535-011-0474-y","article-title":"Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease","volume":"47","author":"Imaeda","year":"2012","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","volume":"382","author":"Wang","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cyto.2019.154859_b0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohns Colitis."},{"key":"10.1016\/j.cyto.2019.154859_b0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.cyto.2019.154859_b0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/096228029900800204","article-title":"Measuring agreement in method comparison studies","volume":"8","author":"Bland","year":"1999","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.cyto.2019.154859_b0115","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1756284818783613","key":"10.1016\/j.cyto.2019.154859_b0120","article-title":"Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels","volume":"11","author":"P\u00e9rez","year":"2018","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0125","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1007\/s10620-018-5144-y","article-title":"Comparison of point-of-care and classical immunoassays for the monitoring infliximab and antibodies against infliximab in IBD","volume":"63","author":"Nasser","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.cyto.2019.154859_b0130","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2019.154859_b0135","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association institute clinical guidelines committee. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cyto.2019.154859_b0140","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2019.154859_b0145","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/MIB.0000000000001223","article-title":"Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study","volume":"23","author":"Roblin","year":"2017","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.cyto.2019.154859_b0150","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jcag\/gwy009.157","article-title":"The threshold for infliximab trough levels leading to dose escalation differs between Crohn\u2019s disease and ulcerative colitis","volume":"1","author":"Cookson","year":"2018","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"10.1016\/j.cyto.2019.154859_b0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/BOR.0b013e3283521c4e","article-title":"Immunogenicity of biological therapeutics: from assay to patient","volume":"24","author":"Krieckaert","year":"2012","journal-title":"Curr. Opin. Rheumatol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619302881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619302881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:55:02Z","timestamp":1760907302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466619302881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":31,"alternative-id":["S1043466619302881"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2019.154859","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2019.154859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154859"}}